Immunicon Corp. entered into two separate research agreements with AstraZeneca UK Ltd. for three projects related to the development of methodologies to identify and quantify certain cell types circulating in blood that are potentially valuable biomarkers for targeted therapies. Leon Terstappen, chief scientific officer of Immunicon, remarked, “We are very pleased to enter into these collaborations with AstraZeneca. We hope that the new assays that we plan to develop under the resear...